Транскатетерная имплантация аортального клапана
Авторы:
Организация:
Кардиохирургический центр Университетской клиники Лейпцига; Штрюмпельштрассе, 39, 04289,
Германия
Для корреспонденции: Сведения доступны для зарегистрированных пользователей.
Тип статьи: Рентгенэндоваскулярные методы диагностики и лечения
DOI:
Ключевые слова:
Скачать (Download)
Аннотация
Традиционное хирургическое протезирование аортального клапана (АК) является «золотым стандартом» лечения пациентов с критическим аортальным стенозом, позволяющее улучшить продолжительсность и качество жизни. Транскатетерная имплантация аортального клапана (Transcatheter Aortic Valve Implantation – TAVI) служит альтернативным методом лечения неоперабельных больных с критическим аортальных стенозом или пациентов с высоким риском. Метод требует мультидисциплинарного подхода, включающего так называемую «Heart Team»: кардиохирурга, кардиолога и анестезиолога. У неоперабельных больных с критическим аортальным стенозом TAVI обладает значительно лучшими результатами по сравнению с медикаментозной терапией и вальвулопластикой. Кроме того, ранние исходы TAVI и хирургического протезирования АК у пациентов с высоким риском сопоставимы.
Литература
Holmes D.R. Jr, Mack M.J., Kaul S. et al. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J. Am. Coll. Cardiol. 2012; 59: 1200.
Piazza N., Kalesan B., van Mieghem N. et al. A 3-center comparison of 1-year mortality outcomes between transcatheter aortic valve implantation and surgical aortic valve replacement on the basis of propensity score matching among intermediate-risk surgical patients. JACC Cardiovasc. Interv. 2013; 6: 443.
Wenaweser P., Stortecky S., Schwander S. et al. Clinical outcomes of patients with estimated low or intermediate surgical risk undergoing transcatheter aortic valve implantation. Eur Heart J. 2013; 34: 1894.
Cribier A., Eltchaninoff H., Tron C. et al. Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience. J. Am. Coll. Cardiol. 2006; 47: 1214.
Zajarias A., Cribier A.G. Outcomes and safety of percutaneous aortic valve replacement. J. Am. Coll. Cardiol. 2009; 53: 1829.
Petronio A.S., De Carlo M., Bedogni F. et al. Safety and efficacy of the subclavian approach for transcatheter transcatheter aortic valve implantation with the CoreValve revalving system. Circ. Cardiovasc. Interv. 2010; 3: 359.
Lardizabal J.A., O'Neill B.P., Desai H.V. et al. The transaortic approach for transcatheter aortic valve replacement: initial clinical experience in the United States. J. Am. Coll. Cardiol. 2013; 61: 2341.
Leon M.B., Smith C.R., Mack M. et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N. Engl. J. Med. 2010; 363: 1597.
Makkar R.R., Fontana G.P., Jilaihawi H. et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N. Engl. J. Med. 2012; 366: 1696.
Popma J.J., Adams D.H., Reardon M.J. et al. Transcatheter aortic valve replacement using a selfexpanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J. Am. Coll. Cardiol. 2014; 63: 1972.
Smith C.R., Leon M.B., Mack M.J. et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N. Engl. J. Med. 2011; 364: 2187.
Kodali S.K., Williams M.R., Smith C.R. et al. Twoyear outcomes after transcatheter or surgical aorticvalve replacement. N. Engl. J. Med. 2012; 366: 1686.
Adams D.H., Popma J.J., Reardon M.J. et al. Transcatheter aortic-valve replacement with a selfexpanding prosthesis. N. Engl. J. Med. 2014; 370: 1790.
Mohr F.W., Holzhey D., Möllmann H. et al The German Aortic Valve Registry: 1-year results from 13,680 patients with aortic valve disease. GARY Executive Board, European Journal of Cardio-Thoracic Surgery: Official Journal of The European Association for Cardio-Thoracic Surgery. 2014; 46 (5): 808–16.
Abdel-Wahab M., Mehilli J., Frerker C. et al. Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: the CHOICE randomized clinical trial. JAMA 2014; 311: 1503.
Panchal H.B., Ladia V., Amin P., Patel P., Veeranki S.P., Albalbissi K. et al. A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events in patients undergoing transfemoral versus transapical transcatheter aortic valve implantation using edwards valve for severe aortic stenosis. Am. J. Cardiol. 2014; 114: 1882–90.
Dvir D., Webb J.G., Bleiziffer S. et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014; 312: 162–70.
Ribeiro H.B., Nombela-Franco L., Urena M. et al. Coronary obstruction following transcatheter aortic valve implantation: a systematic review. JACC Cardiovasc. Interv. 2013; 6: 452.
Aminian A., Lalmand J., Dolatabadi D. Late contained aortic root rupture and ventricular septal defect after transcatheter aortic valve implantation. Catheter Cardiovasc. Interv. 2013; 81: E72.
Walther T., Hamm C.W., Schuler G., Berkowitsch A., Kotting J., Mangner N. et al. Perioperative Results and Complications in 15,964 Transcatheter Aortic Valve Replacements: Prospective Data From the GARY Registry. J. Am. Coll. Cardiol. 2015; 65: 2173–80.
Schymik G., Heimeshoff M., Bramlage P. et al. Ruptures of the device landing zone in patients undergoing transcatheter aortic valve implantation: an analysis of TAVI Karlsruhe (TAVIK) patients. Clin. Res. Cardiol. 2014, 103: 912–20.
Webb J., Gerosa G., Lefe` vre T. et al. Multicenter Evaluation of a Next-Generation Balloon-Expandable Transcatheter Aortic Valve. J. Am. Coll. Cardiol. 2014; 64 (21): 2244–5.
Siontis G.C., Jüni P., Pilgrim T. et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a metaanalysis. J. Am. Coll. Cardiol. 2014; 64: 129–40.
Rode' s-Cabau J., Webb J.G., Cheung A. et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J. Am. Coll. Cardiol. 2010; 55: 1080.
Binder R.K., Webb J.G., Toggweiler S. et al. Impact of post-implant SAPIEN XT geometry and position on conduction disturbances, hemodynamic performance, and paravalvular regurgitation. JACC Cardiovasc. Interv. 2013; 6: 462.
Sinning J.M., Vasa-Nicotera M., Chin D. et al. Evaluation and management of paravalvular aortic regurgitation after transcatheter aortic valve replacement. J. Am. Coll. Cardiol. 2013, 62: 11–20.
Daneault B., Kirtane A.J., Kodali S.K. et al. Stroke associated with surgical and transcatheter treatment of aortic stenosis: a comprehensive review. J. Am. Coll. Cardiol. 2011; 58: 2143.
Thomas M., Schymik G., Walther T. et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: A European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2010; 122: 62.
Himbert D., Descoutures F., Al-Attar N. et al. Results of transfemoral or transapical aortic valve implantation following a uniform assessment in high-risk patients with aortic stenosis. J. Am. Coll. Cardiol. 2009; 54: 303.
Ewe S.H., Delgado V., Ng A.C. et al. Outcomes after transcatheter aortic valve implantation: transfemoral versus transapical approach. Ann. Thorac. Surg. 2011; 92: 1244.
Kahlert P., Knipp S.C., Schlamann M. et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusionweighted magnetic resonance imaging study. Circulation. 2010; 121: 870.
Barbash I.M., Dvir D., Ben-Dor I. et al. Prevalence and effect of myocardial injury after transcatheter aortic valve replacement. Am. J. Cardiol. 2013; 111: 1337.
Carrabba N., Valenti R., Migliorini A. et al. Prognostic value of myocardial injury following transcatheter aortic valve implantation. Am. J. Cardiol. 2013; 111: 1475.
Об авторах
Беляев Сергей Александрович, доктор мед. наук, профессор;
Леонтьев Сергей Андреевич, доктор мед. наук, приват-доцент;
Фридрих-Вильгельм Мор, доктор мед. наук, профессор.